BIVI vs. NRBO, KALA, SYBX, TCRT, LUMO, ORGS, COCP, MEIP, INDP, and SLGL
Should you be buying BioVie stock or one of its competitors? The main competitors of BioVie include NeuroBo Pharmaceuticals (NRBO), KALA BIO (KALA), Synlogic (SYBX), Alaunos Therapeutics (TCRT), Lumos Pharma (LUMO), Orgenesis (ORGS), Cocrystal Pharma (COCP), MEI Pharma (MEIP), Indaptus Therapeutics (INDP), and Sol-Gel Technologies (SLGL). These companies are all part of the "pharmaceutical preparations" industry.
NeuroBo Pharmaceuticals (NASDAQ:NRBO) and BioVie (NASDAQ:BIVI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, community ranking, earnings, dividends, analyst recommendations, valuation and profitability.
1.4% of NeuroBo Pharmaceuticals shares are held by institutional investors. Comparatively, 4.6% of BioVie shares are held by institutional investors. 0.5% of NeuroBo Pharmaceuticals shares are held by company insiders. Comparatively, 4.8% of BioVie shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
NeuroBo Pharmaceuticals currently has a consensus target price of $10.00, suggesting a potential upside of 114.59%. BioVie has a consensus target price of $8.00, suggesting a potential upside of 1,526.68%. Given NeuroBo Pharmaceuticals' higher probable upside, analysts clearly believe BioVie is more favorable than NeuroBo Pharmaceuticals.
BioVie's return on equity of -90.22% beat NeuroBo Pharmaceuticals' return on equity.
NeuroBo Pharmaceuticals received 11 more outperform votes than BioVie when rated by MarketBeat users. Likewise, 75.00% of users gave NeuroBo Pharmaceuticals an outperform vote while only 64.00% of users gave BioVie an outperform vote.
In the previous week, BioVie had 2 more articles in the media than NeuroBo Pharmaceuticals. MarketBeat recorded 3 mentions for BioVie and 1 mentions for NeuroBo Pharmaceuticals. NeuroBo Pharmaceuticals' average media sentiment score of 0.31 beat BioVie's score of 0.00 indicating that BioVie is being referred to more favorably in the news media.
NeuroBo Pharmaceuticals has a beta of -0.23, suggesting that its stock price is 123% less volatile than the S&P 500. Comparatively, BioVie has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500.
Summary
NeuroBo Pharmaceuticals and BioVie tied by winning 6 of the 12 factors compared between the two stocks.
Get BioVie News Delivered to You Automatically
Sign up to receive the latest news and ratings for BIVI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BIVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
